Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California, with news flow centered on development of its investigational Hemopurifier device. Company announcements highlight progress in oncology and infectious disease programs, capital markets activity, and regulatory interactions that shape the outlook for AEMD stock.
Recent news releases describe Aethlon’s ongoing safety, feasibility, and dose-finding oncology trial in Australia, where the Hemopurifier is being evaluated in patients with solid tumors who have not responded to anti-PD-1 therapies. Updates have covered early observations on extracellular vesicles, microRNAs, and lymphocyte counts in initial cohorts, along with protocol amendments and site activity. The company also reports collaborations in Long COVID research, including preclinical data showing that its GNA affinity resin binds extracellular vesicles in Long COVID plasma and depletes EV-associated microRNAs linked to inflammatory pathways.
Investors following AEMD news will also see regular disclosures on financing transactions, such as public offerings and private placements of common stock, pre-funded warrants, and common stock purchase warrants. These items detail gross proceeds, warrant terms, and intended uses of capital for clinical trials, research and development, and working capital. Additional coverage includes patent issuances related to Long COVID and COVID-19-associated coagulopathy, Nasdaq listing compliance updates, and scheduling of quarterly financial results and conference calls.
This news page aggregates Aethlon Medical’s press releases and related coverage so readers can review clinical updates, scientific publications, financing events, and regulatory milestones in one place. For those tracking AEMD, it offers a structured view of how the company communicates progress on the Hemopurifier and its broader development strategy over time.
Aethlon Medical (Nasdaq: AEMD) will present at the Emerging Growth Conference on February 25, 2026 from 12:30–1:00 PM ET. The live, interactive online presentation features a fireside chat with CEO and CFO Jim Frakes and a real-time Q&A for investors.
Registration is required to attend; an archived webcast will be posted on EmergingGrowth.com and the Emerging Growth YouTube channel after the event.
Aethlon Medical (Nasdaq: AEMD) reported fiscal Q3 results for the period ended December 31, 2025, while advancing clinical and R&D programs. Key facts: cash balance ~$7.0 million, Q3 operating loss of $2.06 million, and nine-month operating expenses down 26.9%. Cohort 2 enrollment in the Australian oncology trial is underway, EV Long COVID preclinical data published on bioRxiv, and an MTA with Stavro is evaluating Hemopurifier compatibility with a simplified blood treatment system.
Aethlon Medical (Nasdaq: AEMD) will release fiscal third quarter results for the period ended December 31, 2025 at 4:15 p.m. ET on February 12, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and corporate developments.
Registered participants receive dial-in details; a replay will be available about one hour after the call through March 12, 2026 with conference ID 3024961.
Aethlon Medical (Nasdaq: AEMD) entered a private placement and warrant inducement to raise approximately $3.3 million in gross proceeds, expected to close on or about December 8, 2025. The company agreed to sell 595,897 shares of common stock (or pre-funded warrants) together with warrants to purchase an aggregate 1,042,820 shares at a combined effective offering price of $4.03 per share and accompanying warrant.
The investor agreed to exercise March 2025 warrants for 155,000 shares and September 2025 warrants for 55,555 shares at an amended exercise price of $4.03, and the company will issue 368,471 new unregistered warrants. All warrants will have a $4.03 exercise price and expire 5.5 years after shareholder approval. Maxim Group is sole placement agent.
Aethlon Medical (Nasdaq: AEMD) reported a preclinical ex vivo study (preprint posted 20 Nov 2025) showing the Hemopurifier's GNA affinity resin binds extracellular vesicles (EVs) in Long COVID plasma and decreases seven EV-associated microRNAs linked to inflammatory pathways.
The study found elevated large (100–500 nm) and small (40–200 nm) EVs in Long COVID samples versus recovered controls, increased mannose-positive large EVs, and correlated removal of small EVs by GNA resin. Pathway analysis suggested reduction of inflammatory signaling including JAK-STAT and increased tissue-repair signals. The paper is submitted for peer review.
Aethlon Medical (Nasdaq: AEMD) reported fiscal Q2 results for the period ended September 30, 2025 and provided a corporate update on clinical and research programs.
Key financials include $5.8M cash, a 48% reduction in operating expenses to ~$1.5M for the quarter, and an operating loss of $1.5M vs $2.8M year-ago. Clinical progress includes recruitment of Cohort 2 in the Australian oncology Hemopurifier trial and early biomarker changes observed in 3 initial participants. Collaboration with UCSF on Long COVID EV analysis and an evaluation of Hemopurifier compatibility with a simplified blood treatment system were also announced.
Aethlon Medical (Nasdaq: AEMD) will release fiscal second quarter results for the period ended September 30, 2025 on Wednesday, November 12, 2025 at 4:15 p.m. ET. Management will host a conference call the same day at 4:30 p.m. ET to review results and recent corporate developments, followed by a Q&A.
Registered participants will receive dial-in instructions; toll-free and international dial-in numbers are provided. A replay will be available approximately one hour after the call through December 12, 2025 via the company website or provided dial-in numbers (replay ID 1454680).
The release reiterates that Aethlon is advancing the investigational Hemopurifier, an extracorporeal device targeting enveloped viruses and tumor-derived extracellular vesicles, and notes its U.S. FDA Breakthrough Device Designation for specified oncology and viral indications.
Aethlon Medical (NASDAQ: AEMD) reported early clinical observations from the first three patients in an Australian safety, feasibility and dose‑finding trial of the Hemopurifier in cancer patients refractory to anti‑PD‑1 therapy. Investigators observed directional decreases in certain extracellular vesicles (EVs), PD‑L1+ EV subsets, and 7 of 10 measured microRNAs in two patients after a single 4‑hour treatment, plus increases in total and subset T cells in some participants. Changes generally returned to baseline in 1–3 weeks.
The release cautions these are preliminary observations from three patients with limited follow‑up and are not evidence of clinical benefit.
Aethlon Medical (Nasdaq: AEMD) reported preliminary biological changes from the first cohort (3 patients) in its Australian safety, feasibility and dose‑finding oncology trial of the Hemopurifier.
Key observations after a single 4‑hour Hemopurifier treatment: decreases in large EVs and platelet‑derived EVs in two patients, EV PD‑L1 decreased in all three, 7 of 10 microRNAs decreased in two patients, and increases in total T cells, CD8, CD4 and tumor‑specific (CD137+) T cells were noted. EV and microRNA levels generally returned to baseline within 1–3 weeks.
The company emphasized caveats: a 3‑patient cohort with one withdrawal, single treatments only, directional descriptive results only, and no claim of clinical efficacy or dose response without larger trials.
Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company focused on cancer and infectious disease treatments, has announced the pricing of a $4.5 million public offering. The offering consists of 5,000,000 shares of common stock (or pre-funded warrants) and warrants to purchase up to 5,000,000 additional shares at a combined price of $0.90 per share.
The accompanying warrants will have an exercise price of $0.90 per share, exercisable immediately with a five-year expiration term. The offering, expected to close around September 5, 2025, is being managed by Maxim Group LLC as the exclusive placement agent. Proceeds will fund general corporate purposes, including clinical trials, R&D, and working capital.